Scholarlink

Purpose <p>Neoadjuvant chemotherapy (NAC) using docetaxel/cisplatin/5-fluorouracil (DCF) for locally advanced esophageal cancer (EC) showed better clinical outcomes than conventional regimens; however, had high incidence of serious adverse events.</p> Methods <p>Patients who underwent radical esophagectomy after neoadjuvant-DCF were classified into two-course and three-course groups (<i>n</i> = 60 and 41). Multiple clinical indicators related to nutrition and skeletal muscle that were reported to be associated with survival outcomes were compared between the two groups.</p> Results <p>Changes in prognostic nutritional index (PNI), geriatric nutritional risk index (GNRI), and psoas muscle area (PMA) were significantly low in the three-course group (<i>p</i> &lt; 0.001, &lt; 0.001, and = 0.003). Multivariate analyses for PNI change rate showed initial PNI &lt; 45 and three-course DCF as independent associated factors (<i>B</i> = 0.129; <i>p</i> &lt; 0.001 and <i>B</i> =  − 0.057; <i>p</i> = 0.022); GNRI change rate showed body mass index ≥ 21, initial PNI &lt; 45, and three-course DCF as independent associated factors (B =  − 0.033; <i>p</i> &lt; 0.001, <i>B</i> = 0.062; <i>p</i> &lt; 0.001, and <i>B</i> =  − 0.059; <i>p</i> &lt; 0.001); PMA change rate showed three-course DCF and cStage IV as independent associated factors (<i>B</i> =  − 0.024; <i>p</i> = 0.011 and <i>B</i> =  − 0.025; <i>p</i> = 0.038). There were not significant differences in the long-term survivals between the two groups in pStages I–IV.</p> Conclusions <p>Two courses were superior to three courses for improving nutritional status and mitigating skeletal muscle decreasing during NAC–DCF for EC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel + cisplatin + 5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Kazuaki Matsui,
  • Yutaka Miyawaki,
  • Ryota Kobayashi,
  • Masatoshi Yoshizawa,
  • Tetsuro Toriumi,
  • Gen Ebara,
  • Hiroshi Sato,
  • Shinichi Sakuramoto

摘要

Purpose

Neoadjuvant chemotherapy (NAC) using docetaxel/cisplatin/5-fluorouracil (DCF) for locally advanced esophageal cancer (EC) showed better clinical outcomes than conventional regimens; however, had high incidence of serious adverse events.

Methods

Patients who underwent radical esophagectomy after neoadjuvant-DCF were classified into two-course and three-course groups (n = 60 and 41). Multiple clinical indicators related to nutrition and skeletal muscle that were reported to be associated with survival outcomes were compared between the two groups.

Results

Changes in prognostic nutritional index (PNI), geriatric nutritional risk index (GNRI), and psoas muscle area (PMA) were significantly low in the three-course group (p < 0.001, < 0.001, and = 0.003). Multivariate analyses for PNI change rate showed initial PNI < 45 and three-course DCF as independent associated factors (B = 0.129; p < 0.001 and B =  − 0.057; p = 0.022); GNRI change rate showed body mass index ≥ 21, initial PNI < 45, and three-course DCF as independent associated factors (B =  − 0.033; p < 0.001, B = 0.062; p < 0.001, and B =  − 0.059; p < 0.001); PMA change rate showed three-course DCF and cStage IV as independent associated factors (B =  − 0.024; p = 0.011 and B =  − 0.025; p = 0.038). There were not significant differences in the long-term survivals between the two groups in pStages I–IV.

Conclusions

Two courses were superior to three courses for improving nutritional status and mitigating skeletal muscle decreasing during NAC–DCF for EC.